Yabao Pharma partners to deliver LFB's Vialebex human albumin in China

Chinese specialty drugmaker Yabao Pharmaceutical (SSE: 600351) has entered into a strategic partnership with LFB Biomedicaments, a subsidiary of French state-owned LFB SA, to deliver LFB’s leading human albumin product Vialebex to China, which is the world’s largest human albumin market with annual growth of 29% from 2010 to 2014.

Under the terms of the agreement, Yabao receives exclusive rights to register Vialebex with the China Food and Drug Administration (CFDA) and further commercialize the product in China. LFB will exclusively supply Vialebex to Yabao using its specific expertise in bioproduction and biosafety. Financial terms of the accord were not disclosed.

"LFB’s Vialebex is a human albumin already registered and marketed in Europe and worldwide, commented Dr Peng Wang, president of R&D and head of international business, at Yabao, DDING: "This ground-breaking commercial partnership with LFB is an important sign of Yabao's growing commitment to bringing world-class products such as Vialebex to China. Yabao is pleased to serve the growing need for high-quality human albumin to treat patients suffering from serious diseases in China."